Login to Your Account

Canbridge nabs rights to Aveo's ErbB3 antibody for esophageal cancer

By Shannon Ellis
Staff Writer

Monday, March 21, 2016

SHANGHAI – Canbridge Life Sciences Ltd., a privately held biopharma in Beijing, has in-licensed AV-203, a clinical-stage ErbB3 (HER3) inhibitory antibody candidate from Aveo Oncology Inc., of Cambridge, Mass.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription